[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334399-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334399-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-phase-ii-study-of-induction-pd-1-blockade-nivolumab-in-patients-with-surgically-completely-resectable-mismatch-repair-deficient-endometrial-cancer-nivec-clinical-trial-protocol","A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC) - Clinical Trial Protocol","","Mismatch repair deficient (MMRd) endometrial cancers are highly immunogenic and are of strong interest for immune checkpoint inhibition, yet the complete response rate after PD-1 blockade plus surgery in this population remains insufficiently characterized. This multicenter, single-arm phase II study evaluates induction nivolumab for surgically resectable MMRd endometrial cancer. Thirty patients will be treated with nivolumab every 4 weeks up to 6 months, followed by standard surgery and/or adjuvant therapy. Primary endpoints include clinical and pathological CR rates, with secondary response, survival, and adverse events plus correlative immune and ctDNA analyses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-phase-ii-study-of-induction-pd-1-blockade-nivolumab-in-patients-with-surgically-completely-resectable-mismatch-repair-deficient-endometrial-cancer-nivec-clinical-trial-protocol/334399/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-phase-ii-study-of-induction-pd-1-blockade-nivolumab-in-patients-with-surgically-completely-resectable-mismatch-repair-deficient-endometrial-cancer-nivec-clinical-trial-protocol/334399.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of this phase II trial (NIVEC)?","Question",{"text":63,"@type":64},"To evaluate induction PD-1 blockade with nivolumab in patients with surgically completely resectable MMRd endometrial cancer and determine the complete response rate after treatment and surgery.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who is eligible to participate in the study?",{"text":68,"@type":64},"Patients with clinical stage I–IIIC2 and tumor specimens demonstrating MMRd by immunohistochemistry or microsatellite instability are included, while those with multiple primary cancers or residual adverse effects from prior therapy or surgery effects are excluded.",{"name":70,"@type":61,"acceptedAnswer":71},"How is nivolumab administered and what are the key endpoints?",{"text":72,"@type":64},"Nivolumab 480 mg is given intravenously every 4 weeks for up to 6 months, followed by standard surgery and/or adjuvant treatment. Primary endpoints are clinical CR rate and pathological CR rate; secondary endpoints include response rate, progression-free survival, overall survival, and adverse events.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334399,1790169071,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":22,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","J Gynecol Oncol. 2025 May;36(3):e35 [https://doi.org/10.3802/jgo.2025.36.e35](https://doi.org/10.3802/jgo.2025.36.e35)[ ](https://doi.org/10.3802/jgo.2025.36.e35)pISSN 2005-0380·eISSN 2005-0399  \nClinical Trial Protocol  \nReceived: May 5, 2024  \nRevised: Jul 15, 2024  \nAccepted: Aug 27, 2024  \nPublished online: Oct 23, 2024  \nCorrespondence to  \nJung-Yun Lee  \nDepartment of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Email: [jungyunlee@yuhs.ac](jungyunlee@yuhs.ac)  \n© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nYong Jae Lee  [https://orcid.org/0000-0003-0297-3116](https://orcid.org/0000-0003-0297-3116)[ ](https://orcid.org/0000-0003-0297-3116)[Yoo-Young Lee](Yoo-Young Lee)  [https://orcid.org/0000-0001-5902-9877](https://orcid.org/0000-0001-5902-9877)[ ](https://orcid.org/0000-0001-5902-9877)[Jeong-Yeol Park](Jeong-Yeol Park)  [https://orcid.org/0000-0003-2475-7123](https://orcid.org/0000-0003-2475-7123)[ ](https://orcid.org/0000-0003-2475-7123)[Hyun-Woong Cho](Hyun-Woong Cho)  [https://orcid.org/0000-0002-7114-6301](https://orcid.org/0000-0002-7114-6301)[ ](https://orcid.org/0000-0002-7114-6301)Myong Cheol Lim  [https://orcid.org/0000-0001-8964-7158](https://orcid.org/0000-0001-8964-7158)[ ](https://orcid.org/0000-0001-8964-7158)Mi Kyung Kim  [https://orcid.org/0000-0001-6829-332X](https://orcid.org/0000-0001-6829-332X)[ ](https://orcid.org/0000-0001-6829-332X)[Jong-Min Lee](Jong-Min Lee)  [https://orcid.org/0000-0002-0562-5443](https://orcid.org/0000-0002-0562-5443)  \nA phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)  \nYong Jae Lee ,1 Yoo-Young Lee ,2 Jeong-Yeol Park ,3 Hyun-Woong Cho ,4 Myong Cheol Lim ,5 Mi Kyung Kim ,6 Jong-Min Lee ,7 Jung-Yun Lee  1  \n1Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Seoul, Korea  \n2Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea  \n3Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea  \n4Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea  \n5Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea  \n6Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine, Seoul, Korea 7Department of Obstetrics and Gynecology, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea  \nABSTRACT  \nBackground: Mismatch repair deficient (MMRd) tumors are known to be highly immunogenic and of great interest for immune checkpoint inhibitor. However, there is no data about the complete response (CR) rate of programmed cell death protein 1 (PD-1) blockade and surgery in subjects with MMRd surgically resectable endometrial cancer. In this regard, we suggest a window of opportunity study of induction PD-1 blockade (nivolumab) inpatients with surgically resectable MMRd endometrial cancer.  \nMethods: This is a multicenter, single-arm phase II trial. A total of 30 surgically resectable MMRd endometrial cancer patients will be enrolled. Inclusion criteria include clinical stage I–IIIC2, tumor specimen that demonstrates MMRd by immunohistochemistry or microsatellite instability. Excl","cbCairBUxcdURePQ","https://ap.wps.com/l/cbCairBUxcdURePQ","pdf",1092579,"English","# Abstract\n## Background\n## Methods\n## Trial Registration and Keywords\n# Synopsis\n# Introduction","[{\"question\":\"What is the main objective of this phase II trial (NIVEC)?\",\"answer\":\"To evaluate induction PD-1 blockade with nivolumab in patients with surgically completely resectable MMRd endometrial cancer and determine the complete response rate after treatment and surgery.\"},{\"question\":\"Who is eligible to participate in the study?\",\"answer\":\"Patients with clinical stage I–IIIC2 and tumor specimens demonstrating MMRd by immunohistochemistry or microsatellite instability are included, while those with multiple primary cancers or residual adverse effects from prior therapy or surgery effects are excluded.\"},{\"question\":\"How is nivolumab administered and what are the key endpoints?\",\"answer\":\"Nivolumab 480 mg is given intravenously every 4 weeks for up to 6 months, followed by standard surgery and/or adjuvant treatment. Primary endpoints are clinical CR rate and pathological CR rate; secondary endpoints include response rate, progression-free survival, overall survival, and adverse events.\"}]","A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC) - Clinical Trial Protocol | PDF",1790006506,[146],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/8fc48ff71275476df78cd0343b3c76ec.webp",983,1310]